US StockDetailed Quotes

Provided by Tiger Fintech (Singapore) Pte. Ltd.

Onestream Inc

21.26

+0.16000.76%

Post-market: 21.16-0.1000-0.47%16:07 EDT

Volume:587.42K

Turnover:12.45M

Market Cap:3.74B

PE:-17.04

High:21.36

Open:21.12

Low:20.94

Close:21.10

Loading ...

Overview Company News Filings

Biotech Stock Roundup: CORT Up on Study Data, Updates From AXSM, BMY, EXEL & More

OS Therapies to Host Analyst Day at NYSE on April 7, 2025

CORT Shares Rise as Relacorilant Combo Meets Ovarian Cancer Study Goal

CNS Pharmaceuticals Reports Full Year 2024 Financial Results

ACCESS Newswire

Tovecimig (CTX-009) Meets Primary Endpoint in the Ongoing Randomized Phase 2/3 Study in Patients with Biliary Tract Cancer

Press Release: OS Therapies Reports Full Year 2024 Financial Results and Provides Business Update

FDA Approves AstraZeneca's Imfinzi As First Perioperative Immunotherapy For Muscle-Invasive Bladder Cancer Patients

TIVDAK® (tisotumab vedotin) Approved by European Commission for Previously Treated Recurrent or Metastatic Cervical Cancer

Primary Endpoint Met in Corcept’s Pivotal Phase 3 ROSELLA Trial of Relacorilant in Patients with Platinum-Resistant Ovarian Cancer

OS Therapies Provides Regulatory Update on Rare Pediatric Cancer Immunotherapy Candidate OST-HER2 for Human Osteosarcoma

IMFINZI® (durvalumab) approved in the US as first and only perioperative immunotherapy for patients with muscle-invasive bladder cancer

BeiGene Receives Positive CHMP Opinion for TEVIMBRA® as a First-Line Treatment for Extensive-Stage Small Cell Lung Cancer

Press Release: Genelux Corporation Reports Fourth Quarter and Full Year 2024 Financial Results and Provides Business Update

FDA approves Novartis radioligand therapy Pluvicto® for earlier use before chemotherapy in PSMA-positive metastatic castration-resistant prostate cancer

OneStream Is Maintained at Buy by Goldman Sachs

Hyundai’s EVs are about to get smarter and more efficient with its new ‘Pleos’ brand

IMNN: Protocol in Place for Phase 3 Trial of IMNN-001 in Ovarian Cancer…

Zacks Small Cap Research

Press Release: Tempest Reports Year End 2024 Financial Results and Provides Business Update

Press Release: BioAtla Reports Fourth Quarter and Full Year 2024 Financial Results and Highlights Recent Progress

Japanese Drug Regulator Approves Genmab Cancer Drug For Patients With Advanced Cervical Cancer

{"basename":"","ssrTDKData":{"titleTemplate":"%s - Tiger Brokers","title":"Tiger Brokers | Global Stocks, Options & Futures Trading App","description":"Tiger Brokers, one-stop investment in US stocks, SGX stocks, HK stocks, A-shares & other global assets. One of the best stock trading platforms in Singapore.","keywords":"tiger brokers,tiger trade,tiger brokers singapore,broker online,stock trading in singapore,share trading singapore,brokerage firm singapore,trading app,stock broker singapore,stock trading platforms,trading account","social":{"ogDescription":"Tiger Brokers, one-stop investment in US stocks, SGX stocks, HK stocks, A-shares & other global assets. One of the best stock trading platforms in Singapore.","ogImage":"https://c1.itigergrowtha.com/portal5/static/media/og-logo.be62fbe1.png","ogUrl":"https://www-web.itiger.com/stock/OS/news?page=3"},"companyName":"Tiger Brokers"},"pageData":{"isMobile":false,"isTiger":false,"isTTM":true,"region":"SGP","license":"TBSG","edition":"fundamental","symbol":"OS","isAnalysisPage":false},"__swrFallback__":{"@#url:\"https://hq.skytigris.cn/stock_info/detail/global\",params:#delay:false,,method:\"POST\",data:#items:@#symbol:\"OS\",,,,,undefined,":{"symbol":"OS","market":"US","secType":"STK","nameCN":"Onestream Inc","latestPrice":21.26,"timestamp":1745956800000,"preClose":21.1,"halted":0,"volume":587421,"hourTrading":{"tag":"盘后","latestPrice":21.16,"preClose":21.26,"latestTime":"16:07 EDT","volume":7055,"amount":149947.28,"timestamp":1745957229565},"delay":0,"floatShares":70199725,"shares":176023203,"eps":-1.247698,"marketStatus":"Not Yet Opened","change":0.16,"latestTime":"04-29 16:00:00 EDT","open":21.12,"high":21.36,"low":20.94,"amount":12446409.44113,"amplitude":0.019905,"askPrice":0,"askSize":0,"bidPrice":0,"bidSize":0,"shortable":3,"etf":0,"ttmEps":-1.247698,"tradingStatus":0,"nextMarketStatus":{"tag":"Pre-Mkt","tradingStatus":1,"beginTime":1746000000000},"marketStatusCode":0,"adr":0,"listingDate":1721793600000,"exchange":"NASDAQ","adjPreClose":21.1,"preHourTrading":{"tag":"盘前","latestPrice":21.01,"preClose":21.1,"latestTime":"04:37 EDT","volume":7,"amount":148.56999499999998,"timestamp":1745915844247},"postHourTrading":{"tag":"盘后","latestPrice":21.16,"preClose":21.26,"latestTime":"16:07 EDT","volume":7055,"amount":149947.28,"timestamp":1745957229565},"volumeRatio":0.755198,"impliedVol":0.8449,"impliedVolPercentile":0.9468},"@#url:\"https://hq.skytigris.cn/stock_info/fundamental/all\",params:#delay:false,,method:\"POST\",data:#items:@#symbol:\"OS\",,,,,undefined,":{"symbol":"OS","floatShares":70199725,"roa":"-33.71%","roe":"-102.65%","lyrEps":-1.232998,"volumeRatio":0.755198,"shares":176023203,"dividePrice":0,"high":21.36,"amplitude":0.019905,"preClose":21.1,"low":20.94,"week52Low":16.6942,"pbRate":"9.69","psRate":"7.65","week52High":35.39,"institutionHeld":0,"latestPrice":21.26,"eps":-1.247698,"divideRate":0,"volume":587421,"delay":0,"ttmEps":-1.247698,"open":21.12,"prevYearClose":28.52,"prevWeekClose":21.29,"prevMonthClose":21.34,"prevQuarterClose":21.34,"fiveDayClose":19.79,"twentyDayClose":21.34,"sixtyDayClose":29.78,"earningDate":1746633600000,"earningTime":"盘后"},"$inf$@#url:\"https://stock-news.skytigris.cn/v2/news/list\",params:#symbols:\"OS\",pageSize:20,pageCount:3,lang_content:\"en\",edition:\"fundamental\",,,undefined,":[{"items":[{"id":"2524449342","title":"Biotech Stock Roundup: CORT Up on Study Data, Updates From AXSM, BMY, EXEL & More","url":"https://stock-news.laohu8.com/highlight/detail?id=2524449342","media":"Zacks","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2524449342?lang=en_us&edition=fundamental","pubTime":"2025-04-03 03:00","pubTimestamp":1743620400,"startTime":"0","endTime":"0","summary":"It was a busy week in the biotech sector, marked by significant regulatory and pipeline updates. Among these, shares of Corcept Therapeutics Incorporated CORT skyrocketed after a late-stage study met its primary goal. On the other hand, Axsome Therapeutics’ AXSM shares declined after announcing results from a study on major depressive disorder .Shares of Corcept Therapeutics Incorporated surged on March 31 after the company announced the success of the late-stage ROSELLA study.The phase III ROSELLA study evaluated its pipeline candidate, relacorilant, in combination with nab-paclitaxel for treating patients with platinum-resistant ovarian cancer.Axsome Therapeutics announced top-line data from the phase III PARADIGM study, which evaluated solriamfetol for the treatment of major depressive disorder  with and without severe excessive daytime sleepiness .Nonetheless, in the prespecified subgroup of patients with severe EDS, treatment with solriamfetol led to greater improvements in depres","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://finance.yahoo.com/news/biotech-stock-roundup-cort-study-190000499.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"yahoofinance","symbols":["AXSM","LU0306807586.USD","IE00BJJMRZ35.SGD","LU1571399168.USD","LU0882574055.USD","LU2360032135.SGD","BK4585","BK4007","LU0225284248.USD","LU0985481810.HKD","LU1670710588.SGD","BK4534","LU1670710661.SGD","LU1670711123.USD","LU2242646821.SGD","OS","LU2242652126.USD","IE00BSNM7G36.USD","BK4532","LU0321505868.SGD","BK4505","LU1074936037.SGD","LU1868836757.USD","BLUE","LU0306806265.USD","LU0096364046.USD","CORT","LU1585245621.USD","LU1989771016.USD","BMY","EXEL","LU0321505439.SGD","LU1093756325.SGD","LU0566484027.USD","LU1868836591.USD","LU1291159041.SGD","LU2125154778.USD","LU1718418525.SGD","IE00BJT1NW94.SGD","LU1093756168.USD","BK4097","LU1670711040.USD","LU1323610961.USD","LU2125154935.USD","BK4578","BK4588","PFS","LU0456855351.SGD","BK4556","IE00B2B36J28.USD"],"gpt_icon":1},{"id":"2524649204","title":"OS Therapies to Host Analyst Day at NYSE on April 7, 2025","url":"https://stock-news.laohu8.com/highlight/detail?id=2524649204","media":"Business Wire","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2524649204?lang=en_us&edition=fundamental","pubTime":"2025-04-02 19:40","pubTimestamp":1743594000,"startTime":"0","endTime":"0","summary":"NEW YORK, April 02, 2025----OS Therapies  , a clinical-stage immunotherapy and Antibody Drug Conjugate  biopharmaceutical company, today announced that the Company will be hosting an Analyst Day at the New York Stock Exchange in Lower Manhattan that will start at 10am on Monday, April 7, 2025.The Company intends to focus the Analyst Day discussion on:. OST-HER2 program for human recurrent, fully resected lung metastatic osteosarcoma that is being positioned for Accelerated Approval in late 2025. OST-HER2 program for canine osteosarcoma that is being positioned for conditional approval in the second half of 2025, and plans for full approval. OST-HER2 data in breast cancer, and other human solid tumors to be pursued immediately after approval of OST-HER2 in osteosarcoma. Additionally, the Company will review the pipeline of assets being acquired from Ayala Pharmaceuticals, and potential of our tunable drug conjugates  & antibody drug conjugates  platform.New York Stock Exchange, 18 Broad","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://finance.yahoo.com/news/os-therapies-host-analyst-day-114000741.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"yahoofinance","symbols":["BK4585","BK4139","NYSE","BK4588","BK4080","BK4218","OS","OSTX","BK4231","HST","DC","BK4097","ADC","BK4017","BK4181"],"gpt_icon":0},{"id":"2524128774","title":"CORT Shares Rise as Relacorilant Combo Meets Ovarian Cancer Study Goal","url":"https://stock-news.laohu8.com/highlight/detail?id=2524128774","media":"Zacks","labels":["dataReport"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2524128774?lang=en_us&edition=fundamental","pubTime":"2025-04-01 22:50","pubTimestamp":1743519000,"startTime":"0","endTime":"0","summary":"Shares of Corcept Therapeutics Incorporated CORT were up a staggering 109.1% on March 31 after the company announced data from the phase III ROSELLA study, which evaluated its pipeline candidate, relacorilant, in combination with nab-paclitaxel for treating patients with platinum-resistant ovarian cancer.The ROSELLA study met its primary endpoint of improved progression-free survival, as assessed by blinded independent central review .Per management, data from the ROSELLA study suggested that the combo of relacorilant plus nab-paclitaxel has the potential to become a new standard of care for patients with platinum-resistant ovarian cancer.Year to date, shares of Corcept have skyrocketed 126.7% against the industry’s decline of 1.9%.The phase III ROSELLA study evaluated relacorilant in combination with nab-paclitaxel for treating patients with recurrent, platinum-resistant ovarian cancer.Data from the same showed that treatment with relacorilant plus nab-paclitaxel reduced the risk of d","market":"nz","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://finance.yahoo.com/news/cort-shares-rise-relacorilant-combo-145000011.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"dataReport","news_rank":0,"length":0,"strategy_id":0,"source":"yahoofinance","symbols":["BK4097","CTMX","LU0566484027.USD","BK4007","LU2065171311.SGD","BK4532","FOLD","LU2065170008.USD","CORT","LU1559883803.SGD","ANIP","LU2065171402.SGD","LU2065169927.USD","BK4139","OS"],"gpt_icon":0},{"id":"2524115923","title":"CNS Pharmaceuticals Reports Full Year 2024 Financial Results","url":"https://stock-news.laohu8.com/highlight/detail?id=2524115923","media":"ACCESS Newswire","labels":["dataReport"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2524115923?lang=en_us&edition=fundamental","pubTime":"2025-04-01 20:05","pubTimestamp":1743509100,"startTime":"0","endTime":"0","summary":"Company advancing plans to develop TPI 287, a novel, late stage abeotaxane that is potentially blood brain barrier permeable with published clinical efficacy data in glioblastoma multiforme  for treatment of brain malignancies. CNS Pharmaceuticals plans to engage the FDA and obtain feedback on the design of a study potentially focused on the registration of TPI 287 in recurrent GBM in 2025.The Company recently reported results from the primary analysis of Berubicin in second line treatment of glioblastoma multiforme . The trial compared Berubicin to Lomustine, a current standard of care in GBM. The analysis did not demonstrate statistically significant superiority in overall survival, the primary endpoint. However, although the trial was","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://finance.yahoo.com/news/cns-pharmaceuticals-reports-full-2024-120500175.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"dataReport","news_rank":0,"length":0,"strategy_id":0,"source":"yahoofinance","symbols":["BK4007","BK4211","CNS","CNSP","BK4097","OS","PFS","BK4195","BK4135"],"gpt_icon":0},{"id":"2524194196","title":"Tovecimig (CTX-009) Meets Primary Endpoint in the Ongoing Randomized Phase 2/3 Study in Patients with Biliary Tract Cancer","url":"https://stock-news.laohu8.com/highlight/detail?id=2524194196","media":"GlobeNewswire","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2524194196?lang=en_us&edition=fundamental","pubTime":"2025-04-01 19:00","pubTimestamp":1743505200,"startTime":"0","endTime":"0","summary":"Tovecimig (a DLL4 x VEGF-A bispecific antibody) in combination with paclitaxel achieved a 17.1% overall response rate (ORR), including one complete response, compared to 5.3% ORR for paclitaxel alone,","market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.globenewswire.com/news-release/2025/04/01/3053162/0/en/Tovecimig-CTX-009-Meets-Primary-Endpoint-in-the-Ongoing-Randomized-Phase-2-3-Study-in-Patients-with-Biliary-Tract-Cancer.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["LU1169589451.USD","CMPX","BK4195","CR","SD","IE0002270589.USD","BK4211","LU1169590202.USD","PR","IE00B19Z3B42.SGD","BK4161","ORR","BK4213","PFS","NE","IE00B19Z3581.USD","PD","BK4092","BK4139","BK4097","BTC","OS","IE00B7SZLL34.SGD","BK4023"],"gpt_icon":0},{"id":"2524972201","title":"Press Release: OS Therapies Reports Full Year 2024 Financial Results and Provides Business Update","url":"https://stock-news.laohu8.com/highlight/detail?id=2524972201","media":"Dow Jones","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2524972201?lang=en_us&edition=fundamental","pubTime":"2025-04-01 04:30","pubTimestamp":1743453000,"startTime":"0","endTime":"0","summary":"-- Full data from OST-HER2 Phase 2b osteosarcoma trial, including synthetic. control arm data being developed at the request of FDA to support a. Breakthrough Therapy Designation request, to be presented at MIB Factor. regulatory approval by year-end 2025, triggering issuance of a Priority. OS Therapies Inc.  , a clinical-stage cancer immunotherapy and antibody drug conjugate biotechnology company, today reported full-year 2024 financial results ended December 31, 2024 and provided a business update.OS Therapies' lead product candidate, OST-HER2, is a cancer immunotherapy biologic drug candidate comprised of HER2 bioengineered form of the Lm that mimics a listeria infection of HER2 overexpressing cancer cells and triggers a strong, immune response against cancer cells expressing HER2. This off-the-shelf immunotherapy is designed to prevent metastasis, delay recurrence, kill primary tumors expressing HER2 and increase overall surv","market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://dowjonesnews.com/newdjn/logon.aspx?AL=N","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["BK4080","BK4139","BK4231","SAM","BK4532","BK4588","OS","BK4158","DC","BK4097","BK4585","ADC","OSTX","BK4017","IPO"],"gpt_icon":0},{"id":"2524097658","title":"FDA Approves AstraZeneca's Imfinzi As First Perioperative Immunotherapy For Muscle-Invasive Bladder Cancer Patients","url":"https://stock-news.laohu8.com/highlight/detail?id=2524097658","media":"Benzinga","labels":["productRelease"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2524097658?lang=en_us&edition=fundamental","pubTime":"2025-04-01 02:36","pubTimestamp":1743446174,"startTime":"0","endTime":"0","summary":"The U.S. Food and Drug Administration  on Monday approved AstraZeneca Plc's  Imfinzi in combination with gemcitabine and cisplatin as neoadjuvant treatment, followed by Imfinzias adjuvant monotherapyafter radical cystectomy  for adult patients with muscle-invasive bladder cancer .The FDA approval was based on results from the NIAGARA Phase 3 trial.In a planned interim analysis, the Imfinzi-basedperioperative regimen demonstrated a 32% reduction in the risk of disease progression, recurrence, not undergoing surgery, or death versus the comparator arm.Also Read: AstraZeneca's Imfinzi-Based Regimen Shows Improved Event-Free Survival In Early-Stage Gastric Cancer Patients. Results from the key secondary endpoint of overall survival  showed that the Imfinzi-based perioperative regimen reduced the risk of death by 25% versus neoadjuvant chemotherapy with radical cystectomy.Concurrently, AstraZeneca'sCalquence in combination with bendamustine and rituximab was recommended for approval in the ","market":"nz","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://finance.yahoo.com/news/fda-approves-astrazenecas-imfinzi-first-183614282.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"productRelease","news_rank":0,"length":0,"strategy_id":0,"source":"yahoofinance","symbols":["LU2417539215.USD","BK4568","LU2456880835.USD","BK4588","AZN","LU0320765992.SGD","OS","LU1829250122.USD","BK4097","BK4585","LU0109394709.USD","LU2462157665.USD","LU2236285917.USD","BK4007","LU0889565916.HKD"],"gpt_icon":0},{"id":"2523092138","title":"TIVDAK® (tisotumab vedotin) Approved by European Commission for Previously Treated Recurrent or Metastatic Cervical Cancer","url":"https://stock-news.laohu8.com/highlight/detail?id=2523092138","media":"GlobeNewswire","labels":["productRelease"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2523092138?lang=en_us&edition=fundamental","pubTime":"2025-03-31 23:20","pubTimestamp":1743434400,"startTime":"0","endTime":"0","summary":"Media Release COPENHAGEN, Denmark; March 31, 2025 TIVDAK is the first and only antibody-drug conjugate (ADC) approved to treat recurrent or metastatic cervical cancer with disease progression on or af","market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.globenewswire.com/news-release/2025/03/31/3052498/0/en/TIVDAK-tisotumab-vedotin-Approved-by-European-Commission-for-Previously-Treated-Recurrent-or-Metastatic-Cervical-Cancer.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"productRelease","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["EC","IE00BBT3K403.USD","ADC","LU0053666078.USD","BK4550","IE0002270589.USD","L","SG9999001176.USD","LU1894683264.USD","BK4599","LU1057294990.SGD","SG9999013999.USD","BK4107","BK4534","LU0170899867.USD","LU0122379950.USD","LU0225284248.USD","LU0306806265.USD","SG9999011175.SGD","BK4585","IE00B19Z3B42.SGD","LU0985481810.HKD","LU0058720904.USD","BK4097","LU0321505439.SGD","IE00B19Z3581.USD","BK4007","LU0321505868.SGD","SG9999003800.SGD","BK4592","ORR","LU1883839398.USD","LU0289739699.SGD","BK4231","SG9999002224.SGD","IE00BLSP4452.SGD","LU0234572021.USD","BK4533","PFS","LU0868494617.USD","BK4201","SGXZ57979304.SGD","LU1066051498.USD","MAA","BK4080","IE000M9KFDE8.USD","BK4581","OS"],"gpt_icon":1},{"id":"2523946601","title":"Primary Endpoint Met in Corcept’s Pivotal Phase 3 ROSELLA Trial of Relacorilant in Patients with Platinum-Resistant Ovarian Cancer","url":"https://stock-news.laohu8.com/highlight/detail?id=2523946601","media":"Business Wire","labels":["dataReport"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2523946601?lang=en_us&edition=fundamental","pubTime":"2025-03-31 20:00","pubTimestamp":1743422400,"startTime":"0","endTime":"0","summary":"Relacorilant plus nab-paclitaxel improved progression-free and overall survival and did not increase side effect burden. Results will support a New Drug Application  in the United States and a Marketing Authorization Application  in Europe. Relacorilant plus nab-paclitaxel has the potential to become a new standard of care for patients with platinum-resistant ovarian cancer. REDWOOD CITY, Calif., March 31, 2025----Corcept Therapeutics Incorporated , a commercial-stage company engaged in the discovery and development of medications to treat severe endocrinologic, oncologic, metabolic and neurologic disorders by modulating the effects of the hormone cortisol, today announced that ROSELLA, the company’s pivotal Phase 3 trial of relacorilant plus nab-paclitaxel in patients with platinum-resistant ovarian cancer, met its primary endpoint of improved progression-free survival, as assessed by blinded independent central review .\"Patients with advanced ovarian cancer have few good treatment op","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://finance.yahoo.com/news/primary-endpoint-met-corcept-pivotal-120000306.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"dataReport","news_rank":0,"length":0,"strategy_id":0,"source":"yahoofinance","symbols":["LU1559883803.SGD","BK4585","BK4215","EC","BK4007","BK4588","LU0566484027.USD","BK4532","OS","MAA","CORT","BK4201","BK4097"],"gpt_icon":0},{"id":"2523456169","title":"OS Therapies Provides Regulatory Update on Rare Pediatric Cancer Immunotherapy Candidate OST-HER2 for Human Osteosarcoma","url":"https://stock-news.laohu8.com/highlight/detail?id=2523456169","media":"Business Wire","labels":["policyRegulatory"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2523456169?lang=en_us&edition=fundamental","pubTime":"2025-03-31 19:40","pubTimestamp":1743421200,"startTime":"0","endTime":"0","summary":"New canine elite responder biomarkers added to human biomarker strategy. NEW YORK, March 31, 2025----OS Therapies  , a clinical-stage immunotherapy and Antibody Drug Conjugate  biopharmaceutical company, today provided a regulatory update for its OST-HER2 listeria monocytogenes  immunotherapeutic cancer biologic drug candidate in the prevention or delay of fully-resected, recurrent, lung metastatic osteosarcoma.\"We are making rapid progress in putting together an appropriate data package to achieve accelerated approval for OST-HER2 given the feedback we’ve received to date from the FDA,\" said Paul Romness, MHP, Chairman & CEO of OS Therapies. \"We know one of the US government’s stated priorities is to treat deadly childhood cancers, and we believe that OST-HER2 for osteosarcoma aligns well with that mission.\". The Company initiated regulatory correspondence with the US Food & Drug Administration  and the United Kingdom’s Medicines and Healthcare products Regulatory Agency  in the first","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://finance.yahoo.com/news/os-therapies-provides-regulatory-rare-114000177.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"policyRegulatory","news_rank":0,"length":0,"strategy_id":0,"source":"yahoofinance","symbols":["OS","BK4543","BK4139","DC","NICE","BK4080","BK4148","BK4097","IE00BFMHRM44.USD","OSTX","BK4023","BK4017","BK4566","ADC","OST","BK4231"],"gpt_icon":0},{"id":"2523491061","title":"IMFINZI® (durvalumab) approved in the US as first and only perioperative immunotherapy for patients with muscle-invasive bladder cancer","url":"https://stock-news.laohu8.com/highlight/detail?id=2523491061","media":"Business Wire","labels":["productRelease"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2523491061?lang=en_us&edition=fundamental","pubTime":"2025-03-31 19:00","pubTimestamp":1743418800,"startTime":"0","endTime":"0","summary":"Based on NIAGARA Phase III trial results which showed a 32% reduction in the risk of recurrence and a 25% reduction in the risk of death vs. neoadjuvant chemotherapy alone. WILMINGTON, Del., March 31, 2025----AstraZeneca’s IMFINZI  in combination with gemcitabine and cisplatin as neoadjuvant treatment, followed by IMFINZI as adjuvant monotherapy after radical cystectomy  has been approved in the US for the treatment of adult patients with muscle-invasive bladder cancer .The approval was granted by the Food and Drug Administration  after securing Priority Review and was based on results from the NIAGARA Phase III trial which were presented during a Presidential Symposium at the 2024 European Society for Medical Oncology  Congress and simultaneously published in The New England Journal of Medicine.In the trial, patients were treated with four cycles of IMFI","market":"nz","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://finance.yahoo.com/news/imfinzi-durvalumab-approved-us-first-110000141.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"2","news_top_title":null,"news_tag":"productRelease","news_rank":0,"length":0,"strategy_id":0,"source":"yahoofinance","symbols":["BK4585","NICE","BK4007","BK4124","LU2236285917.USD","BK4543","LU2462157665.USD","BK4132","VOD","LU0109394709.USD","BK4213","BK4568","BK4006","CRT","LU0889565916.HKD","LU2417539215.USD","BK4532","LU1829250122.USD","BK4144","BK4566","AZN","TEN","LU0320765992.SGD","IE00BFMHRM44.USD","HSCT","LU2456880835.USD","HCC","BK4097","BK4023","BK4588","OS"],"gpt_icon":0},{"id":"2523141809","title":"BeiGene Receives Positive CHMP Opinion for TEVIMBRA® as a First-Line Treatment for Extensive-Stage Small Cell Lung Cancer","url":"https://stock-news.laohu8.com/highlight/detail?id=2523141809","media":"Business Wire","labels":["productRelease"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2523141809?lang=en_us&edition=fundamental","pubTime":"2025-03-31 18:00","pubTimestamp":1743415200,"startTime":"0","endTime":"0","summary":"Positive opinion for first-line treatment of extensive-stage small cell lung cancer based on results of RATIONALE-312 study demonstrating statistically significant overall survival benefit for TEVIMBRA in combination with chemotherapy. SAN CARLOS, Calif., March 31, 2025----BeiGene, Ltd. , a global oncology company that intends to change its name to BeOne Medicines Ltd., today announced that the Committee for Medicinal Products for Human Use  of the European Medicines Agency issued a positive opinion recommending approval of TEVIMBRA , in combination with etoposide and platinum chemotherapy, as a first-line treatment for adult patients with extensive-stage small cell lung cancer .\"The aggressive nature of extensive-stage small cell lung cancer makes it an extremely difficult type of lung cancer to treat, and currently available treatments may not adequately control disease progression,\" said Prof. Silvia Novello, M.D., Ph.D., President Women Against Lung Cancer in Europe  and Head of Me","market":"nz","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://finance.yahoo.com/news/beigene-receives-positive-chmp-opinion-100000003.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"productRelease","news_rank":0,"length":0,"strategy_id":0,"source":"yahoofinance","symbols":["BK4087","BK4139","CHMP","ONC","ITT","LU0053671581.USD","BK4097","SSI","OS","LU0054578231.USD","BK4161"],"gpt_icon":0},{"id":"2523434680","title":"Press Release: Genelux Corporation Reports Fourth Quarter and Full Year 2024 Financial Results and Provides Business Update","url":"https://stock-news.laohu8.com/highlight/detail?id=2523434680","media":"Dow Jones","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2523434680?lang=en_us&edition=fundamental","pubTime":"2025-03-29 04:10","pubTimestamp":1743192600,"startTime":"0","endTime":"0","summary":"Genelux Corporation Reports Fourth Quarter and Full Year 2024 Financial Results and Provides Business Update. -- Positive Preliminary Phase 1b/2 Data of Olvi-Vec in Advanced Small-Cell Lung Cancer --. -- Matt Pulisic joined the company as its new Chief Financial Officer --. -- Closing of $10.5 Million Underwritten Offering of Common Stock --. -- $30.9 million in cash, cash equivalents and short-term investments --. WESTLAKE VILLAGE, Calif., March 28, 2025  -- Genelux Corporation , a late clinical-stage immuno-oncology company, reported fourth quarter and full year 2024 financial results and business updates.\"Our progress in the fourth quarter of 2024 and into 2025 marks a pivotal period for patients, our company, and our investors,\" said Thomas Zindrick, President, CEO and Chairman of Genelux. \"We are pleased with the continued progress and promise of our clinical development program. The strengthening of our management team, with the addition of Matt, and of our balance sheet, with ou","market":"other","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://dowjonesnews.com/newdjn/logon.aspx?AL=N","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["BK4097","OS","PFS","TM","BK4211","03160","BK4555","BK4585","BK4588","BK4604","GNLX","BK4139","BK4195","BK4099"],"gpt_icon":0},{"id":"2523856256","title":"FDA approves Novartis radioligand therapy Pluvicto® for earlier use before chemotherapy in PSMA-positive metastatic castration-resistant prostate cancer","url":"https://stock-news.laohu8.com/highlight/detail?id=2523856256","media":"GlobeNewswire","labels":["productRelease"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2523856256?lang=en_us&edition=fundamental","pubTime":"2025-03-29 00:52","pubTimestamp":1743180720,"startTime":"0","endTime":"0","summary":"New indication approximately triples eligible patient population, allowing Pluvicto to be used after one androgen receptor pathway inhibitor  and now before chemotherapy. Pluvicto significantly reduced risk of progression or death by 59% and more than doubled median radiographic progression-free survival  vs. change in ARPI in Phase III PSMAfore trial*. Approximately half of patients do not live long enough to receive a second treatment for mCRPC, highlighting need for earlier use of effective therapies with demonstrated tolerability1. Multiple RLT manufacturing facilities in US fully meet supply needs for expanded indication, with industry-leading infrastructure to accelerate delivery of RLTs to patients. Basel, March 28, 2025 – Novartis announced today that the US Food and Drug Administration  approved Pluvicto  for patients with prostate-specific membrane antigen -positive metastatic castration-resistant prostate cancer  who have been treated with an androgen receptor pathway inhibi","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://finance.yahoo.com/news/fda-approves-novartis-radioligand-therapy-165200923.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"productRelease","news_rank":0,"length":0,"strategy_id":0,"source":"yahoofinance","symbols":["LU0211331839.USD","LU0320765489.SGD","IE00B2B36J28.USD","IE00BFTCPJ56.SGD","OS","LU0070302665.USD","NVS","LU0208291251.USD","IE0002141913.USD","BK4578","BK4097","BK4588","BK4007","BK4532","IE00BJJMRZ35.SGD","IE00B4R5TH58.HKD","BK4585","IE0009355771.USD","IE00BJT1NW94.SGD"],"gpt_icon":0},{"id":"2523507579","title":"OneStream Is Maintained at Buy by Goldman Sachs","url":"https://stock-news.laohu8.com/highlight/detail?id=2523507579","media":"Dow Jones","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2523507579?lang=en_us&edition=fundamental","pubTime":"2025-03-29 00:02","pubTimestamp":1743177720,"startTime":"0","endTime":"0","summary":"Ratings actions from Benzinga: https://www.benzinga.com/quote/OS/analyst-ratings \n\n\n \n\n\n  (END) Dow Jones Newswires\n\n\n  March 28, 2025 12:02 ET (16:02 GMT)","market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":["rate"],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://dowjonesnews.com/newdjn/logon.aspx?AL=N","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["OS"],"gpt_icon":0},{"id":"2523500282","title":"Hyundai’s EVs are about to get smarter and more efficient with its new ‘Pleos’ brand","url":"https://stock-news.laohu8.com/highlight/detail?id=2523500282","media":"Electrek","labels":["productRelease"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2523500282?lang=en_us&edition=fundamental","pubTime":"2025-03-28 23:29","pubTimestamp":1743175768,"startTime":"0","endTime":"0","summary":"Hyundai is quickly evolving into much more than just a traditional automaker. After launching its new software brand and tech platform, “Pleos,” Hyundai promises a new era of high-tech, software-defined vehicles. The advanced new software will be used for the Hyundai, Kia, and Genesis brands.","market":"us","thumbnail":"https://electrek.co/wp-content/uploads/sites/3/2025/03/Hyundai-new-Pleos-brand.jpeg?quality=82&strip=all&w=1400","type":0,"news_type":0,"thumbnails":["https://electrek.co/wp-content/uploads/sites/3/2025/03/Hyundai-new-Pleos-brand.jpeg?quality=82&strip=all&w=1400"],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://electrek.co/2025/03/28/hyundai-evs-smarter-more-efficient-new-pleos-brand/","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"productRelease","news_rank":0,"length":0,"strategy_id":0,"source":"electrek_highlight","symbols":["OS","AVP","BK4097"],"gpt_icon":0},{"id":"2523840506","title":"IMNN: Protocol in Place for Phase 3 Trial of IMNN-001 in Ovarian Cancer…","url":"https://stock-news.laohu8.com/highlight/detail?id=2523840506","media":"Zacks Small Cap Research","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2523840506?lang=en_us&edition=fundamental","pubTime":"2025-03-28 22:19","pubTimestamp":1743171540,"startTime":"0","endTime":"0","summary":"On March 24, 2025, Imunon, Inc.  announced it reached alignment with the U.S. FDA on the protocol for a Phase 3 clinical trial, referred to as OVATION 3, of its lead candidate IMNN-001 for the treatment of women with newly diagnosed advanced ovarian cancer. Trial sites are currently being initiated with the first patient to be enrolled in the near term.The following slide provides the overall design of the trial. Eligible patients will have either Stage IIIc and IV advanced ovarian cancer and will be randomized to receive neoadjuvant chemotherapy , interval debulking surgery, and adjuvant chemotherapy. Patients who are positive for homologous recombination deficiency  are also eligible and will receive poly ADP-ribose polymerase  inhibitor therapy as part of standard-of-care  maintenance therapy. The primary endpoint is overall survival , with secondary endpoints evaluating surgical response score, chemotherapy response score, clinical response , and time to second-line treatment.","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://finance.yahoo.com/news/imnn-protocol-place-phase-3-141900552.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"yahoofinance","symbols":["OS","BK4225","ORR","BK4139","ITT","HR","BK4097","BK4203","LU0054578231.USD","GSD","BK4161","LU0053671581.USD","BK4213","IMNN","SOC"],"gpt_icon":0},{"id":"2522853184","title":"Press Release: Tempest Reports Year End 2024 Financial Results and Provides Business Update","url":"https://stock-news.laohu8.com/highlight/detail?id=2522853184","media":"Dow Jones","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2522853184?lang=en_us&edition=fundamental","pubTime":"2025-03-28 04:10","pubTimestamp":1743106200,"startTime":"0","endTime":"0","summary":"-- Granted Both Orphan Drug & Fast Track designations for Amezalpat  for the treatment of patients with Hepatocellular Carcinoma . -- Announced Agreement with Roche to Support Advancement of Amezalpat Combination Therapy into First-Line HCC Pivotal Trial. -- Received FDA \"Study May Proceed\" letter for Phase 2 trial of TPST-1495 for the treatment of Familial Adenomatous Polyposis . \"2024 was another year filled with significant progress and milestone achievements that position Tempest for a successful future,\" said Stephen Brady, president and chief executive officer of Tempest. \"Despite challenging capital markets, our lean team excelled, reporting key OS data from the ongoing randomized Phase 2 trial of amezalpat in first-line hepatocellular carcinoma. As previously announced, we have secured broad regulatory agreement with both the FDA and EMA on the Phase 3 plan and received both Orphan Drug and Fast Track designations from the FDA. We also advanced our second clinical program, TPST","market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://dowjonesnews.com/newdjn/logon.aspx?AL=N","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["BK4006","NCI","HCC","BK4202","BK4139","OS","BK4097","BK4022","TPST","BK4232","R"],"gpt_icon":0},{"id":"2522539194","title":"Press Release: BioAtla Reports Fourth Quarter and Full Year 2024 Financial Results and Highlights Recent Progress","url":"https://stock-news.laohu8.com/highlight/detail?id=2522539194","media":"Dow Jones","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2522539194?lang=en_us&edition=fundamental","pubTime":"2025-03-28 04:05","pubTimestamp":1743105900,"startTime":"0","endTime":"0","summary":"-- CAB-EpCAM x CAB-CD3  Phase 1 dose-escalation study continues with. data readout expected mid-2025; Dose expansion data readout anticipated. -- Mecbotamab vedotin  Q2W dosing regimen associated with. exceptional overall survival  with 66% and 58% of patients with mKRAS. NSCLC alive at a landmark one-year and two-years, respectively, which. measures expected to further extend runway beyond key clinical readouts. SAN DIEGO, March 27, 2025  -- BioAtla, Inc. , a global clinical-stage biotechnology company focused on the development of Conditionally Active Biologic  antibody therapeutics for the treatment of solid tumors, today announced its financial results for the fourth quarter and full year ended December 31, 2024, and provided highlights on its clinical programs.","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://dowjonesnews.com/newdjn/logon.aspx?AL=N","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["LU2065732104.USD","PRGS","BK4097","BCAB","BK4139","OS"],"gpt_icon":0},{"id":"2522533947","title":"Japanese Drug Regulator Approves Genmab Cancer Drug For Patients With Advanced Cervical Cancer","url":"https://stock-news.laohu8.com/highlight/detail?id=2522533947","media":"Benzinga","labels":["productRelease"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2522533947?lang=en_us&edition=fundamental","pubTime":"2025-03-28 02:27","pubTimestamp":1743100046,"startTime":"0","endTime":"0","summary":"The Japanese Ministry of Health, Labour and Welfare on Thursday approved Genmab A/S’ Tivdak  for advanced or recurrent cervical cancer that has progressed on or after cancer chemotherapy.Tivdak is the first and only antibody-drug conjugate  to be approved for cervical cancer in Japan.The approval is based on data from the Phase 3 innovaTV 301 clinical trial that evaluated the efficacy and safety of TIVDAK compared to chemotherapy in patients with advanced or recurrent cervical cancer who were previously treated with chemotherapy.Also Read: AbbVie/Genmab’s Epkinly FDA Approval Is A Positive Step, Analyst Says Additional Expansion Opportunities Underway. The trial included 502 patients, 101 of which were Japanese.Median OS was 11.5 months among patients treated with Tivdak compared to 9.5 months for patients who received chemotherapy. Secondary endpoints of progression-free survival  and confirmed objective response rate  were also met.This article Japanese Drug Regulator Approves Genmab","market":"nz","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://finance.yahoo.com/news/japanese-drug-regulator-approves-genmab-182726829.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"productRelease","news_rank":0,"length":0,"strategy_id":0,"source":"yahoofinance","symbols":["LU0321505868.SGD","BK4585","BK4534","BK4139","LU1057294990.SGD","BK4007","LU0058720904.USD","ADC","BK4211","IE0031619046.USD","LU0306807586.USD","BK4568","LU1066051498.USD","GMAB","LU0456855351.SGD","BK4533","IE00B19Z4B17.USD","LU0321505439.SGD","BK4599","LU0122379950.USD","BK4550","BK4592","BK4157","SG9999013999.USD","LU0225284248.USD","AEIS","IE00BBT3K403.USD","SG9999001176.SGD","LU0289739699.SGD","LU1894683264.USD","IE00BLSP4452.SGD","BK4195","LU0170899867.USD","PFS","LU1066053197.SGD","ORR","LU0985481810.HKD","SG9999001176.USD","IE00B19Z3B42.SGD","IE00BLSP4239.USD","IE0002270589.USD","LU1883839398.USD","IE000M9KFDE8.USD","IE00B19Z3581.USD","IE00B66KJ199.SGD","LU0234572021.USD","BK4588","OS","IE00B7SZL793.SGD"],"gpt_icon":1}],"pageSize":20,"totalPage":10,"pageCount":3,"totalSize":200,"code":"91000000","status":"200"}],"@#url:\"https://hq.skytigris.cn/fundamental/corporate_actions/details/OS\",params:#limit:5,,,undefined,":[{"date":"2025-05-08","symbol":"OS","type":"earning","reportTimeType":"post","market":"US","fiscalQuarterEnding":"2025/03","expectedEps":-0.06,"defaultRemindTime":1746734400000,"name":null,"time":"Post Market","dateTimestamp":1746676800000,"actualEps":null},{"market":"US","date":"2025-02-11","symbol":"OS","fiscalQuarterEnding":"2024/12","expectedEps":0.02,"name":null,"time":"Post Market","type":"earning","dateTimestamp":1739250000000,"reportTimeType":"post","actualEps":0.07},{"market":"US","date":"2024-11-07","symbol":"OS","fiscalQuarterEnding":"2024/09","expectedEps":0,"name":null,"time":"Post Market","type":"earning","dateTimestamp":1730955600000,"reportTimeType":"post","actualEps":-1.06},{"market":"US","date":"2024-09-03","symbol":"OS","fiscalQuarterEnding":"2024/06","expectedEps":-0.11,"name":null,"time":"Post Market","type":"earning","dateTimestamp":1725336000000,"reportTimeType":"post","actualEps":null}],"@#url:\"https://hq.skytigris.cn/fundamental/dividend/history\",params:#symbol:\"OS\",market:\"US\",,,undefined,":[],"@#url:\"https://hq.skytigris.cn/fundamental/estimate/recommendation\",params:#symbol:\"OS\",market:\"US\",delay:false,,,undefined,":{"strongBuy":0.3333,"buy":0.5556,"hold":0.1111,"sell":0,"strongSell":0,"meanLabel":"BUY","meanPercent":0.5556,"analysts":18,"updateTime":1742356800000},"@#url:\"https://hq.skytigris.cn/value_analysis/stock/OS\",params:#withQuantilePoint:true,period:\"5year\",factor:\"peRate\",delay:false,algorithm:1,,,undefined,":{"brief":{"id":"OS","date":"2025-04-28","current":-17.333565,"percent":0.89011,"low":-1655.61542,"twenty":-1414.621664,"median":-27.407231,"eighty":-18.799104,"high":-14.493656,"avg":-429.05566,"sd":616.357181,"marketCap":3747533991},"quantilePoints":[{"date":"2024-08-02","current":-402.058638,"twenty":-402.058638,"median":-402.058638,"eighty":-402.058638,"marketCap":4348264172},{"date":"2024-08-09","current":-394.529993,"twenty":-398.004752,"median":-394.602383,"eighty":-391.489578,"marketCap":4266841869},{"date":"2024-08-16","current":-420.156344,"twenty":-402.058638,"median":-395.977809,"eighty":-394.529993,"marketCap":4543990864},{"date":"2024-08-23","current":-418.563746,"twenty":-420.156344,"median":-400.248867,"eighty":-394.674774,"marketCap":4526766915},{"date":"2024-08-30","current":-439.701867,"twenty":-427.829772,"median":-415.668113,"eighty":-395.977809,"marketCap":4755375690},{"date":"2024-09-06","current":-1412.285699,"twenty":-434.093948,"median":-420.156344,"eighty":-395.977809,"marketCap":4652069092},{"date":"2024-09-13","current":-1421.532228,"twenty":-630.517125,"median":-426.381956,"eighty":-397.599363,"marketCap":4682527160},{"date":"2024-09-20","current":-1491.611188,"twenty":-1406.835113,"median":-428.55368,"eighty":-398.352228,"marketCap":4913367253},{"date":"2024-09-27","current":-1641.015636,"twenty":-1479.542034,"median":-435.672004,"eighty":-401.33473,"marketCap":5405505506},{"date":"2024-10-04","current":-1582.129844,"twenty":-1582.616503,"median":-445.348351,"eighty":-408.313205,"marketCap":5211535706},{"date":"2024-10-11","current":-1384.546111,"twenty":-1557.991535,"median":-1361.673117,"eighty":-414.50986,"marketCap":4560694889},{"date":"2024-10-18","current":-1422.505547,"twenty":-1506.405635,"median":-1387.466067,"eighty":-417.984619,"marketCap":4685733272},{"date":"2024-10-25","current":-1513.510863,"twenty":-1501.052381,"median":-1410.582391,"eighty":-419.837824,"marketCap":4985504782},{"date":"2024-10-31","current":-1488.204572,"twenty":-1545.825049,"median":-1419.58559,"eighty":-422.588676,"marketCap":4902145859},{"date":"2024-11-08","current":-29.444986,"twenty":-1544.267739,"median":-1421.532228,"eighty":-422.588676,"marketCap":5359016876},{"date":"2024-11-15","current":-29.547337,"twenty":-1525.190689,"median":-1414.232336,"eighty":-406.749563,"marketCap":5377644907},{"date":"2024-11-22","current":-27.361909,"twenty":-1504.167001,"median":-1405.472467,"eighty":-395.977809,"marketCap":4979894851},{"date":"2024-11-29","current":-26.339693,"twenty":-1496.769778,"median":-1384.546111,"eighty":-392.705744,"marketCap":4793850470},{"date":"2024-12-06","current":-28.33551,"twenty":-1493.655158,"median":-903.058146,"eighty":-29.829328,"marketCap":5157091209},{"date":"2024-12-13","current":-28.454992,"twenty":-1490.248542,"median":-439.701867,"eighty":-28.749622,"marketCap":5178836972},{"date":"2024-12-20","current":-27.223413,"twenty":-1484.895288,"median":-431.521704,"eighty":-28.258307,"marketCap":4954688343},{"date":"2024-12-27","current":-27.048786,"twenty":-1479.834029,"median":-428.191726,"eighty":-28.004145,"marketCap":4922906075},{"date":"2025-01-03","current":-25.973452,"twenty":-1479.444702,"median":-426.381956,"eighty":-27.732022,"marketCap":4727194212},{"date":"2025-01-10","current":-24.227183,"twenty":-1479.444702,"median":-422.183287,"eighty":-27.252823,"marketCap":4409371530},{"date":"2025-01-17","current":-26.460569,"twenty":-1468.54353,"median":-415.668113,"eighty":-26.869269,"marketCap":4815850013},{"date":"2025-01-24","current":-27.894348,"twenty":-1465.818237,"median":-402.058638,"eighty":-26.861301,"marketCap":5076799163},{"date":"2025-01-31","current":-27.407231,"twenty":-1462.314289,"median":-396.991281,"eighty":-26.925021,"marketCap":4988143362},{"date":"2025-02-07","current":-27.09474,"twenty":-1459.102337,"median":-394.674774,"eighty":-26.925021,"marketCap":4931269830},{"date":"2025-02-14","current":-19.646244,"twenty":-1457.642359,"median":-390.041762,"eighty":-26.782239,"marketCap":4247537655},{"date":"2025-02-21","current":-19.437413,"twenty":-1455.695721,"median":-30.305187,"eighty":-26.72172,"marketCap":4202388031},{"date":"2025-02-28","current":-18.385222,"twenty":-1452.094441,"median":-29.520901,"eighty":-26.562732,"marketCap":3974903390},{"date":"2025-03-07","current":-18.486889,"twenty":-1446.059864,"median":-28.777108,"eighty":-26.339693,"marketCap":3996883783},{"date":"2025-03-14","current":-16.449855,"twenty":-1440.122619,"median":-28.454992,"eighty":-26.179328,"marketCap":3556475076},{"date":"2025-03-21","current":-17.921046,"twenty":-1437.981318,"median":-28.198548,"eighty":-25.317223,"marketCap":3874548031},{"date":"2025-03-28","current":-18.76981,"twenty":-1430.38943,"median":-27.986257,"eighty":-24.094834,"marketCap":4058051659},{"date":"2025-04-04","current":-16.296269,"twenty":-1422.116219,"median":-27.889753,"eighty":-20.198845,"marketCap":3523269657},{"date":"2025-04-11","current":-15.87621,"twenty":-1419.974918,"median":-27.820821,"eighty":-19.520945,"marketCap":3432452458},{"date":"2025-04-17","current":-15.802935,"twenty":-1417.346957,"median":-27.682957,"eighty":-19.180725,"marketCap":3416610370},{"date":"2025-04-25","current":-17.317281,"twenty":-1415.400319,"median":-27.425612,"eighty":-18.846182,"marketCap":3744013527},{"date":"2025-04-28","current":-17.333565,"twenty":-1414.621664,"median":-27.407231,"eighty":-18.799104,"marketCap":3747533991}],"updateTime":1745980117085}}}